Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

Oct 01 2008

• By Michael McCaughan

Related Content

Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews

Nov 01 2007

How Risky Is Too Risky?

Oct 01 2008

Inhaled Insulin is Dead. Long Live Inhaled Insulin

Mar 01 2008

Novo Nordisk: Riding High on Diabetes

Jun 01 2007

BMS Deals Diabetes Drugs, Solidifies Specialist Stance

Feb 01 2007

Related Companies

Eli Lilly and Company

Merck & Co., Inc.

Wyeth

Sanofi Genzyme

Pfizer Inc.

Novo Nordisk A/S

AstraZeneca PLC

Additional Topics

Business Strategies Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window